← Back to Patent Explorer
US5202120A Expired / Lapsed US ⏱️ 0.0 years remaining

Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes

Assignee: Case Western Reserve University
•
Filing: 1989-10-27
•
Granted: 1993-04-13
•
Expires: 2009-10-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to "activated" immature astrocytes and the methods of utilizing the activated immature astrocytes as a means for promoting Pursuant to the provisions of 35 U.S.C. §202(c), it is hereby acknowledged that the Government has certain rights in this invention, which was made in part with funds from the National Eye Institute of the National Institutes of Health.

Inventors

  • 👤 Jerry Silver
  • 👤 George M. Smith
  • 👤 James W. Jacobberger

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 00:29
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61K; A61K35/00; A61K35/12; A61K35/30; C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0618; C12N5/0622; C12N2510/00; C12N2510/04

Claims Analysis

Total Claims: 64
Claim 1
Independent Claim 33 words
A method for promoting central nervous system axon regeneration comprising: (a) providing activated immature astrocytes; and (b) administering an effective amount of the activated immature astrocytes to damaged axons to promote axon regeneration.
Claim 2
Independent Claim 33 words
A method for promoting central nervous system axon regeneration comprising: (a) providing activated immature astrocytes; and (b) administering an effective amount of the activated immature astrocytes to damaged axons to promote axon regeneration.
Claim 3
Dependent Claim 16 words
The method according to claim 1, in which the activated immature astrocytes are stellate-shaped, GFAP-positive astrocytes.
Claim 4
Dependent Claim 19 words
The method according to claim 1, in which the activated immature astrocytes are embryonic through postnatal day 8 astrocytes.
Claim 5
Dependent Claim 21 words
The method according to claim 1 which further comprises before administering the activated immature astrocytes, substantially purifying the activated immature astrocytes.
Claim 6
Dependent Claim 15 words
The method according to claim 1, in which the activated immature astrocytes are immortalized astrocytes.
Claim 7
Dependent Claim 14 words
The method according to claim 1, in which the damaged axons are forebrain axons.
Claim 8
Dependent Claim 14 words
The method according to claim 1, in which the damaged axons are commissural axons.
Claim 9
Dependent Claim 15 words
The method according to claim 1, in which the damaged axons are spinal cord axons.
Claim 10
Dependent Claim 14 words
The method according to claim 8, in which the spinal axons are sensory axons.
Claim 11
Dependent Claim 22 words
The method according to claim 1, in which the damaged axons are in the dorsal root entry zone of the spinal cord.
Claim 12
Dependent Claim 19 words
The method according to claim 1, 3, 4, 5, 6 or 8 in which the astrocytes are brain astrocytes.
Claim 13
Dependent Claim 13 words
The method according to claim 11 in which the astrocytes are cerebral astrocytes.
Claim 14
Independent Claim 43 words
A method for reducing glial scar formation in damaged central nervous system tissue comprising: (a) providing activated immature astrocytes; and (b) administering an effective amount of the activated immature astrocytes to damaged tissue of the central nervous system to reduce glial scar formation.
Claim 15
Independent Claim 43 words
A method for reducing glial scar formation in damaged central nervous system tissue comprising: (a) providing activated immature astrocytes; and (b) administering an effective amount of the activated immature astrocytes to damaged tissue of the central nervous system to reduce glial scar formation.
Claim 16
Dependent Claim 16 words
The method according to claim 13, in which the activated immature astrocytes are stellate-shaped, GFAP-positive astrocytes.
Claim 17
Dependent Claim 19 words
The method according to claim 13, in which the activated immature astrocytes are embryonic through postnatal day 8 astrocytes.
Claim 18
Dependent Claim 21 words
The method according to claim 13 which further comprises before administering the activated immature astrocytes, substantially purifying the activated immature astrocytes.
Claim 19
Dependent Claim 15 words
The method according to claim 13, in which the activated immature astrocytes are immortalized astrocytes.
Claim 20
Dependent Claim 20 words
The method according to claim 13, in which the damaged tissue of the central nervous system is a forebrain axon.
Claim 21
Dependent Claim 15 words
The method according to claim 18, in which the forebrain axon is a commissural axon.
Claim 22
Dependent Claim 21 words
The method according to claim 13, in which the damaged tissue of the central nervous system is a spinal cord axon.
Claim 23
Dependent Claim 16 words
The method according to claim 20, in which the spinal cord axon is a sensory axon.
Claim 24
Dependent Claim 27 words
The method according to claim 13, in which the damaged tissue of the central nervous system is in the dorsal root entry zone of the spinal cord.
Claim 25
Dependent Claim 19 words
The method according to claim 13, 15, 16, 17, 18 or 20 in which the astrocytes are brain astrocytes.
Claim 26
Dependent Claim 13 words
The method according to claim 23 in which the astrocytes are cerebral astrocytes.
Claim 27
Independent Claim 45 words
A method for promoting blood vessel regeneration in the central nervous system comprising: (a) providing critical period activated immature astrocytes; and (b) administering an effective amount of the activated immature astrocytes to damaged blood vessels in the central nervous system to promote blood vessel regeneration.
Claim 28
Independent Claim 45 words
A method for promoting blood vessel regeneration in the central nervous system comprising: (a) providing critical period activated immature astrocytes; and (b) administering an effective amount of the activated immature astrocytes to damaged blood vessels in the central nervous system to promote blood vessel regeneration.
Claim 29
Dependent Claim 16 words
The method according to claim 25, in which the activated immature astrocytes are stellate-shaped, GFAP-positive astrocytes.
Claim 30
Dependent Claim 19 words
The method according to claim 25, in which the activated immature astrocytes are embryonic through postnatal day 8 astrocytes.
Claim 31
Dependent Claim 15 words
The method according to claim 25, in which the activated immature astrocytes are immortalized astrocytes.
Claim 32
Dependent Claim 21 words
The method according to claim 25 which further comprises before administering the activated immature astrocytes, substantially purifying the activated immature astrocytes.
Claim 33
Dependent Claim 16 words
The method according to claim 25, in which the damaged blood vessels are in the forebrain.
Claim 34
Dependent Claim 17 words
The method according to claim 25, in which the damaged blood vessels are in the spinal cord.
Claim 35
Dependent Claim 23 words
The method according to claim 25, in which the damaged blood vessels are in the dorsal root entry zone of the spinal cord.
Claim 36
Dependent Claim 19 words
The method according to claim 25, 27, 28, 29, 30 and 31 in which the astrocytes are brain astrocytes.
Claim 37
Dependent Claim 13 words
The method according to claim 33, in which the astrocytes are cerebral astrocytes.
Claim 38
Independent Claim 21 words
A method for treating a patient with nerve damage comprising administering an effective amount of activated immature astrocytes to the patient.
Claim 39
Independent Claim 21 words
A method for treating a patient with nerve damage comprising administering an effective amount of activated immature astrocytes to the patient.
Claim 40
Dependent Claim 16 words
The method according to claim 35, in which the activated immature astrocytes are stellate-shaped, GFAP-positive astrocytes.
Claim 41
Dependent Claim 19 words
The method according to claim 35, in which the activated immature astrocytes are embryonic through postnatal day 8 astrocytes.
Claim 42
Dependent Claim 15 words
The method according to claim 35, in which the activated immature astrocytes are immortalized astrocytes.
Claim 43
Dependent Claim 21 words
The method according to claim 35, which further comprises before administering the activated immature astrocytes, substantially purifying the activated immature astrocytes.
Claim 44
Dependent Claim 34 words
The method according to claim 35, 36, 37, 38 or 39 in which the activated immature astrocytes are administered by seeding the astrocytes onto an implant, and inserting the seeded implant into the patient.
Claim 45
Dependent Claim 27 words
The method according to claim 35, 36, 37, 38 or 39 in which the activated immature astrocytes are administered in a media which partly impedes their mobility.
Claim 46
Dependent Claim 17 words
The method according to claim 35, 37, 38 or 39 in which the astrocytes are brain astrocytes.
Claim 47
Dependent Claim 13 words
The method according to claim 40, in which the astrocytes are brain astrocytes.
Claim 48
Dependent Claim 13 words
The method according to claim 42 in which the astrocytes are cerebral astrocytes.
Claim 49
Dependent Claim 13 words
The method according to claim 43 in which the astrocytes are cerebral astrocytes.
Claim 50
Independent Claim 22 words
A method for treating a patient with nerve damage comprising administering an effective amount of olfactory bulb glial cells to the patient.
Claim 51
Independent Claim 22 words
A method for treating a patient with nerve damage comprising administering an effective amount of olfactory bulb glial cells to the patient.
Claim 52
Dependent Claim 17 words
A pharmaceutical composition comprising isolated activated immature astrocytes; and a pharmaceutically acceptable sterile carrier for human administration.
Claim 53
Dependent Claim 17 words
A pharmaceutical composition comprising isolated activated immature astrocytes; and a pharmaceutically acceptable sterile carrier for human administration.
Claim 54
Dependent Claim 16 words
The pharmaceutical composition of claim 47 in which the activated immature astrocytes are stellate-shaped, GFAP-positive astrocytes.
Claim 55
Dependent Claim 19 words
The pharmaceutical composition of claim 47 in which the activated immature astrocytes are embryonic through postnatal day 8 astrocytes.
Claim 56
Dependent Claim 15 words
The pharmaceutical composition of claim 47 in which the activated immature astrocytes are immortalized astrocytes.
Claim 57
Dependent Claim 19 words
The pharmaceutical composition of claim 47, 48, 49, or 50 in which the activated immature astrocytes are substantially purified.
Claim 58
Dependent Claim 16 words
The pharmaceutical composition of claim 47, 49, or 50 in which the astrocytes are brain astrocytes.
Claim 59
Dependent Claim 13 words
The pharmaceutical composition of claim 51 in which the astrocytes are brain astrocytes.
Claim 60
Dependent Claim 13 words
The pharmaceutical composition of claim 52 in which the astrocytes are cerebral astrocytes.
Claim 61
Dependent Claim 13 words
The pharmaceutical composition of claim 53 in which the astrocytes are cerebral astrocytes.
Claim 62
Dependent Claim 18 words
A pharmaceutical composition comprising isolated olfactory bulb glial cells; and a pharmaceutically acceptable sterile carrier for human administration.
Claim 63
Dependent Claim 18 words
A pharmaceutical composition comprising isolated olfactory bulb glial cells; and a pharmaceutically acceptable sterile carrier for human administration.
Claim 64
Dependent Claim 19 words
The pharmaceutical composition of claim 56 in which the olfactory bulb glial cells are immortalized olfactory bulb glial cells.

References Cited (Backward Citations)

US4642291A Cited
US4574116A Cited
US4662884A Cited
US4707448A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-04-12 1996-10-12 1997-04-13 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-04-12 2000-10-12 2001-04-13 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-04-12 2004-10-12 2005-04-13 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag